Deal Spotlight
July 13, 2026
Colossal Biosciences raises €55.2M seed round with Thomas Tull
€55.2M
round size
series-a
stage
The funding round closed on June 19, 2026, with participation from Breyer Capital, Draper Associates, Richard Garriott, Tim Draper, Tony Robbins, and Winklevoss Capital. The company has raised a total of €184M to date.
Colossal Biosciences is a biotechnology firm focused on de-extinction and species preservation, utilizing gene-editing technology. It is headquartered in the United States and operates in the Healthcare & Life Sciences sector at the series-a stage.
Related insights
- Deal SpotlightKARAM Safety raises EUR66M Series C+ with India Business Excellence Fund V and Motilal Oswal Alternates
- Deal SpotlightBOOKR Kids raises €6.1M Series A backed by 3TS Capital Partners and TCV
- Cross-Country AnalysisUS and Israeli startups show near-identical median times from Series B to C+ rounds
- Deal SpotlightOre Energy raises €37.3M Series A backed by HV Capital, Plural, Positron Ventures
Explore the full dataset
Brouky tracks 36,000+ investors and 100,000+ investments across 84,000+startups. Search by country, stage, and sector.